At the news
? BULLISHIMPACT 6/10 6-K filed Jun 1, 2026 at 07:59 ET
BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) plus chemotherapy in first-line non-small cell lung cancer. The data showed a confirmed objective response rate of 57.1% in non-squamous and 68.4% in squamous NSCLC, with a 100% disease control rate, and a manageable safety profile. This is a positive clinical update for a key pipeline asset, but the data are early-stage (Phase 2, n=40) and the stock impact is likely modest given the pre-revenue nature of the company.
- Interim Phase 2 data from ROSETTA Lung-02 trial of pumitamig (BNT327/BMS-986545) plus chemotherapy in first-line advanced NSCLC.
- Confirmed objective response rate (cORR) of 57.1% in non-squamous and 68.4% in squamous NSCLC; disease control rate (DCR) of 100%.
- At the lower dose, cORR was 63.6% for non-squamous and 72.7% for squamous subtypes.
- cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access